

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of

Stephane PAUL

Application No.: 10/565,371

Filed: December 13, 2006

For: NOVEL MULTIFUNCTIONAL  
CYTOKINES



**MAIL STOP**

Group Art Unit: 1646

Examiner: UNKNOWN

Confirmation No.: 7331

**SECOND INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed. However, copies of the listed U.S. patents and U.S. patent application publications are not enclosed since it is no longer required.

The documents are being submitted within three (3) months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later. Since these documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b), no fee or statement is required.

It should be noted that each item of information contained in this Information Disclosure Statement was cited in the attached European Search Report in counterpart European Application No. 07005182.6. Please note that references WO 03/035105 A and WO 01/10912 A, which are cited in the attached European Search Report, were previously submitted with the Information Disclosure Statement filed on December 13, 2006 and therefore are not cited herein.

This Information Disclosure Statement contains information which is not in the English language but was cited in a search report or other action by a foreign patent office in a counterpart foreign application. In accordance with MPEP § 609 III A(3), an English language version of the search report or action which indicates the degree of relevance found by the foreign office is being submitted herewith.

**Foreign Patent Documents**

1. XIAN CHANG LI et al., International Patent Publication No WO 02/22805 A, published 3/21/2002.
2. IZUMI NAKATANI, European Patent No. EP 0 816 510 A1, issued on 1/07/1998.
3. STEPHEN D. GILLIES, International Patent Publication No. WO 03/048334 A, published on 6/12/2003.
4. DR. HANS KRAUSE et al., German Patent No. DE 198 23 351 A1, issued on 12/10/1998.
5. JULIA E. NOVAK et al., International Patent Publication No. WO 00/53761 A, published on 9/14/2000.

**Non-Patent Literature Documents**

1. OZDEMIR ONER ET AL., "Interleukin-2 and Interleukin-15 Combination Induces Lymphokine Activated Killer Cells with Higher Perforin and Granzyme B Expression Patterns and Superior Cytotoxic Response Against Human Leukemia Cells", Blood, November 16, 2002, vol. 100, no. 11, and Abstract No. 1827, 44th Annual Meeting of the American Society of Hematology; Philadelphia, PA, USA, December 06-10, 2002.
2. BAGRIACIK E UMIT ET AL., "CD43 potentiates CD3-induced proliferation of murine intestinal intraepithelial lymphocytes", Immunology and Cell Biology, June 2001, pp. 303-307, vol. 79, no.3.
3. DOBMEYER T S ET AL., "Mechanism of gamma sigma T-Cell-Mediated Inhibition of Stem Cell Differentiation in Vitro: Possible Relevance for Myelosuppression in HIV-Infected Individuals", Cellular Immunology, February 25, 1998, pp. 26-36, vol. 184, no.1, Academic Press.
4. BULFONE-PAUS S ET AL., "Differential Regulation of Human T Lymphoblast Functions by IL2 and IL-15", CytoKine, July 1997, pp. 507-513, vol. 9, no. 7, Academic Press Ltd., Philadelphia, PA, US.
5. VAQUEZ NANCY ET AL., "Interleukin-15 Augments Superoxide Production and Microbicidal Activity of Human Monocytes against Candida albicans", Infection and Immunity, January 1, 1998, pp. 145-150, vol. 66, no. 1, American Society for Microbiology.
6. AVERIL ET AL., "The Pleiotropic Functions of Interleukin 15: Not So Interleukin 2-like After All", Journal of Experimental Medicine, Tokyo, JP, March 6, 2000, pp. 753-755, vol. 191, no. 5, The Rockefeller University Press.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.


The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date: July 18, 2008

By:

  
Susan M. Dadio  
Registration No. 40373

P.O. Box 1404  
Alexandria, VA 22313-1404  
703 836 6620